Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Valvular heart disease accounts for a significant part of cardiovascular disease. The purpose of a survey on valvular heart disease is to evaluate practices and show how physicians act in the diagnosis and management of their patients. The data resulting from this project will provide the basis for the improvement of practice guidelines, targeted educational programmes and new scientific evaluation. Participating hospitals will be able to compare their disease management procedures and outcomes with established guidelines and with the results of other hospitals in the same country, as well as in other countries
The roll-out of this survey during the first months of 2017 is timed to allow the release of the first results simultaneously with the publication of the 2017 ESC/EACTS guidelines on valvular heart disease. This evaluation of real-life practice will form an appropriate reference for targeted educational programmes, followed by subsequent surveys to assess their impact.
The main objective of the VHD II Survey is to:
Other objectives will consist of analyses of the data collected in the program, in order to report in-hospital and six-month mortality and morbidity after enrolment in the survey, according to the chosen management strategy. Specific issues and related questions to be addressed during the study on valvular heart disease will focus on:
The ESC Valvular Heart Disease II Survey is an international, prospective, longitudinal multicentre, observational study in worldwide countries.
Consenting patients who meet the eligibility criteria will be admitted consecutively to the study during a three-month period of recruitment, without any limit to the maximum number of patients included in a centre. Approximately five thousand patients will be enrolled overall.
A six-month follow-up assessment will be made by telephone or during a patient visit by the investigating centre.
Standard management of patients currently performed in routine clinical practice will be followed. Drug prescriptions and indications to perform diagnostic/therapeutic procedures will be completely left to the participating cardiologists.
No specific protocols or recommendations for evaluation, management, and/or treatment will be put forth during this observational study.
All the 56 ESC country members are invited to participate in this survey through the National Cardiac Societies. A national coordinator is appointed for each country to manage the survey at national level.
If you are already registered as a participant in the EORP programme, you may connect to our secure website: http://www.eorp.org.
The Executive Committee of the registry is chaired by Bernard Iung.
Alec Vahanian, Chair of EORP Oversight Committee, FRJeroen Bax, ESC President, NLSusanna Price, GBVictoria Delgado, NLMichele De Bonis, ITBernard Prendergast, UKRaphael Rosenheck, ATOlaf Wendler, DEFrank Ruschitzka, CHMichael Haude, DEBogdan Popescu, ROStephan Windecker, CHGerhard Hindricks, DELuc Pierard, BEAldo Maggioni (ex-officio), EORP Scientific Coordinator, IT
Artan Goda, ALJulia Mascherbauer, ATFuad Samadov, AZBernard Cosyns, BEAgnès Pasquet, BEKrasimira Hristova, BGPeter Wenaweser, CHGeorgios Georghiou, CYKaterina Linhartova, CZHuseyin Ince, DENikolaj Ihlemann, DKPeep Laanmets, EEMagdy Abdelhamid, EGArturo Evangelista, ESAntti Saraste, FIChristophe Tribouilloy, FRShelley Rahman-Haley, GBAndreas Katsaros, GRAstrid Apor, HURonen Beeri, ILFrancesco Romeo, ITErkin Mirrakhimov, KGVaida Mizariene, LTAndrejs Erglis, LVElizabeta Srbinovska Kostovska, MKDaniela Cassar DeMarco, MTJorge Cossio Aranda, MXVictoria Delgado, NLLidia Tomkiewicz-Pajak, PLRegina Ribeiras, PTBogdan A. Popescu, ROBranko Beleslin, RSAlexander Bogachev-Prokophiev, RUIveta Simkova, SKSait Mesut Dogan, TRGani Bajraktari, XK
View all ongoing ESC Registries
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.